Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZD-0473 AstraZeneca.

M P Hay1

  • 1Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. m.hay@auckland.ac.nz

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).

Bioorganic & medicinal chemistry letters·2000
Same author

Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Anti-cancer drug design·1999
Same author

A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.

Bioorganic & medicinal chemistry letters·1999
Same author

Recent developments in the design of bioreductive drugs.

The British journal of cancer. Supplement·1996
Same author

Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1.

The British journal of cancer. Supplement·1996
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

ZD-0473 is a novel platinum (II) complex developed for cisplatin-resistant cancers. Clinical trials are underway for solid tumors, with potential market entry anticipated in 2003.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • ZD-0473, a sterically hindered platinum (II) complex, was designed to overcome cisplatin resistance in cancer treatment.
  • Developed by Johnson Matthey Technology and the Cancer Research Campaign (CRC), it is now under AstraZeneca's development.

Purpose of the Study:

  • To evaluate ZD-0473 as a potential treatment for cisplatin-resistant cancers, particularly solid tumors.
  • To assess the safety, tolerability, and pharmacokinetic profile of ZD-0473 in clinical trials.

Main Methods:

  • Intravenous (i.v.) formulation of ZD-0473 entered Phase II clinical trials for solid tumors in December 1999.
  • Phase I trials in the US, commencing November 1999, focused on determining maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics.

Related Experiment Videos

  • Oral formulation is undergoing preclinical development.

    • Main Results:

    • Phase I trials were conducted to establish safety and pharmacokinetic parameters.
    • Phase II trials for the i.v. formulation commenced for solid tumor treatment.
    • AstraZeneca anticipates filing for registration in Q4 2002.

    Conclusions:

    • ZD-0473 shows promise as a treatment for cisplatin-resistant cancers.
    • Further clinical development and regulatory filings are planned by AstraZeneca.